| Detailed information |
|---|
| CancerLivER ID | 2586 |
| Biomarker | APOC1, SEPP1, PDZGEF1, SCML2, ALDH5A1, BNIP3, FBXW1B, PAH, Homo sapiens clone 24473 mRNA sequence, PACE4, FLJ31305 fis or clone LIVER1000104 or , Unknown or , MIG2, RARRES2, BAAT, KDELR2, RNP24, FACL2, KIAA0977 protein, HADHSC, HADHSC, SDHD, CPB2, PGRMC1, AOP2, PPM1A, SDC1, CCL14, EST |
| Biomarker Name/Symbol (given in Publication) | Apolipoprotein CI or APOC1, Selenoprotein P plasma 1 or SEPP1, PDZ domain containing guanine nucleotide exchange factor 1 or PDZ-GEF1, Sex comb on midleg-like 2 (Drosophila) or SCML2, Aldehyde dehydrogenase 5 family member A1 or ALDH5A1, BCL2/adenovirus E1B 19 kD interacting protein 3 or BNIP3, F-box and WD40 domain protein 1B or FBXW1B, Phenylalanine hydroxylase or PAH, Homo sapiens clone 24473 mRNA sequence or , Paired basic amino acid cleaving system 4 or PACE4, FLJ31305 fis or clone LIVER1000104 or , Unknown or , Mitogen inducible 2 or MIG2, Retinoic acid receptor responder (tazarotene induced) 2 or RARRES2, Bile acid Coenzyme A: amino acid N-acyltransferase or BAAT, KDEL endoplasmic reticulum protein retention receptor 2 or KDELR2, Checkpoint suppressor 1 or CHES1, Coated vesicle membrane protein or RNP24, Fatty-acid Coenzyme A ligase long-chain 2 or FACL2, KIAA0977 protein or KIAA0977, L3-hydroxyacyl Coenzyme A dehydrogenase short chain or HADHSC, L3-hydroxyacyl Coenzyme A dehydrogenase short chain or HADHSC, Succinate dehydrogenase complex subunit D or SDHD, Carboxypeptidase B2 or CPB2, Rogesterone receptor membrane component 1 or PGRMC1, Anti-oxidant protein 2 or AOP2, Protein phosphatase 1A or PPM1A, Syndecan 1 or SDC1, Chemokine (C-C motif) ligand 14 or CCL14, EST |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for grade progression of HCC and associated invasion and with metastsis of HCC; but not validated on indepedent dataset |
| Experimental Condition | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in G3 compared with G2 (with Fisher ratio more than 1.3) |
| Level of significance | P < 0.005 |
| Source | Tissue |
| PMID | 15710396 |
| Type of Biomarker | Prognostic |
| Pathway | cell adhesion, cell growth regulation, immunomod- ulation, apoptosis, and metastasis. |
| Cohort | 76 HCC samples : 50 were sero- positive for HCV antibody (HCVAb) and seronegative for hepatitis B virus surface antigen (HBsAg) and among 50 (7G1 (well differentiated, 35 G2 (moderately differentiated) and 10 G3 (poorly differentiated); 26 were seronegative for HCVAb |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Hepatocellular carcinoma (HCC) samples with positive hepatitis C virus (HCV) serology (well (G1), moderately (G2), and poorly (G3) differentiated tumors) with and without HCV infection. |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |